Japan’s Otsuka Pharmaceutical to buy Temasek-backed Visterra for $430m

Tablets of vitamin supplement imported by Otsuka Pharmaceutical Co. are arranged for a photograph in Tokyo, Japan, on Friday, Sept. 3, 2010. Photographer: Tomohiro Ohsumi/Bloomberg Photo by Bloomberg

Tokyo-based healthcare company Otsuka Pharmaceutical (Otsuka), a subsidiary of Otsuka Holdings, has announced that it has entered into a definitive merger agreement to acquire antibody developer Visterra for $430 million in cash.

Continue reading this story with a subscription to DealStreetAsia.

Subscribe

Should your colleagues be reading this article too? Contact us for corporate subscriptions at subs@dealstreetasia.com.